**Immunization Test Tool Release Notes for Version 2.0.14 July 20, 2023**

**Data**

| **Test Case / Message Profile** | **Issue** | **Resolution** |
| --- | --- | --- |
| For Z22 messages | Per the CDC, the following **Unit of Sale NDC(**s) has/have been added:   * **50090-6180-00** for meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) * **58160-0848-11** for RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF (Arexvy) * **49281-0564-10** for DTaP-IPV (QUADRACEL) * **50090-4958-01** for HPV9 (GARDASIL 9)   Per the CDC, the following Unit of Sale NDC(s) Description(s) has/have been modified   * **Unit of Sale NDC Code 80777-0283-99** **Description**    + “10 mcg/0.2 mL dose **booster** of Original and Omicron BA.4 & BA.5 COVID-19 strains (Moderna)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL” * **Unit of Sale NDC Code 80777-0282-99** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose (Moderna COVID-19 Vaccine Bivalent Booster) 10 MULTI-DOSE VIALS”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose” * **Unit of Sale NDC Code 59267-1404-02** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 12 year and older) 10 SINGLE-DOSE VIALS”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose” * **Unit of Sale NDC Code 59267-0304-02** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 12 year and older) 10 MULTI-DOSE VIALS”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose” * **Unit of Sale NDC Code 59267-0565-02** **Description**    + “**59267-0565-02 for** SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 5 years through 11 years) 10 MULTI-DOSE VIALS”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose” * **Unit of Sale NDC Code 59267-0609-02** **Description**    + “3 mcg/0.2 mL dose Original and Omicron BA.4 & BA.5 COVID-19 strains (Pfizer)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose” | Update(s) has/have been made to the **NDC Unit of Sale Value Set** in the Immunization Test Suite  Added:   * **Code**: 50090-6180-00 * **Code System**: NDC * **Description**: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) * **Code**: 58160-0848-11 * **Code System**: NDC * **Description**: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF (Arexvy) * **Code**: 49281-0564-10 * **Code System**: NDC * **Description**: DTaP-IPV (QUADRACEL) * **Code**: 50090-4958-01 * **Code System**: NDC * **Description**: HPV9 (GARDASIL 9)   Description Modified:   * **Code**: 80777-0283-99 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL * **Code**: 80777-0282-99 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose * **Code**: 59267-1404-02 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose * **Code**: 59267-0304-02 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose * **Code**: 59267-0565-02 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose * **Code**: 59267-0609-02 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
| For Z22 messages | Per the CDC, the following **Unit of Use NDC(s)** has/have been added:   * **50090-6180-01** for meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) * **58160-0723-03** for RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF (Arexvy) * **49281-0564-58** for DTaP-IPV (QUADRACEL) * **50090-4958-00** for HPV9 (GARDASIL 9)   Per the CDC, the following Unit of Use NDC(s) Description(s) has/have been modified   * **Unit of Use NDC Code 80777-0283-02** **Description**    + “10 mcg/0.2 mL dose **booster** of Original and Omicron BA.4 & BA.5 COVID-19 strains (Moderna)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL” * **Unit of Use NDC Code 80777-0282-05** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose (Moderna COVID-19 Vaccine Bivalent **Booster**)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose” * **Unit of Use NDC Code 59267-1404-01** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 12 year and older)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose” * **Unit of Use NDC Code 59267-0304-01** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 12 year and older)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose” * **Unit of Use NDC Code 59267-0565-01** **Description**    + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 5 years through 11 years)”   changed to   * + “COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose” * **Unit of Use NDC Code 59267-0609-01** **Description**    + “3 mcg/0.2 mL dose Original and Omicron BA.4 & BA.5 COVID-19 strains (Pfizer)”   changed to   * “COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose”   The following error in the **Unit of Use** **NDC Value Set** was found:   * **58160-740-02** for rotavirus, live, monovalent vaccine (Rotarix)   should be   * **58160-0740-02** for rotavirus monovalent (Rotarix) | Update(s) has/have been made to the **NDC Unit of Use Value Set** in the Immunization Test Suite  Added:   * **Code**: 50090-6180-01 * **Code System**: NDC * **Description**: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) * **Code**: 58160-0723-03 * **Code System**: NDC * **Description**: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF (Arexvy) * **Code**: 49281-0564-58 * **Code System**: NDC * **Description**: DTaP-IPV (QUADRACEL) * **Code**: 50090-4958-00 * **Code System**: NDC * **Description**: HPV9 (GARDASIL 9)   Description Modified:   * **Code**: 80777-0283-02 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL * **Code**: 80777-0282-05 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose * **Code**: 59267-1404-01 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose * **Code**: 59267-0304-01 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose * **Code**: 59267-0565-01 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose * **Code**: 59267-0609-01 * **Code System**: NDC * **Description**: COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose   Code and Description Corrected:   * **Code**: 58160-0740-02 (from 58160-740-02) * **Code System**: NDC * **Description**: rotavirus monovalent (Rotarix) |
| For Z22, Z32, and Z42 messages | Per the CDC, the following addition(s)/modification(s) has/have been made to the **CVX** table:  Added:   * **CVX code 303** for Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free * **CVX code 304** for Respiratory syncytial virus (RSV), unspecified   Modified Description:   * **CVX Code 230 description updated**   + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 10 mcg/0.2 mL dose (Moderna COVID-19 Vaccine, Bivalent)”   changed to   * + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose” * **CVX Code 301 description updated**   + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 5 years through 11 years)”   changed to   * + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation” * **CVX Code 300 description updated**   + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation (Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster 12 year and older)”   changed to   * + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation” * **CVX Code 229 description updated**   + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent **booster**, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose”   changed to   * + “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose” | Update(s) has/have been made to the **CVX** **Value Set** in the Immunization Test Suite  Added:   * **Code**: 303 * **Code System**: CVX * **Description**: Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free * **Code**: 304 * **Code System**: CVX * **Description**: Respiratory syncytial virus (RSV), unspecified   Description Modified:   * **Code**: 230 * **Code System**: CVX * **Description**: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose * **Code**: 301 * **Code System**: CVX * **Description**: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation * **Code**: 300 * **Code System**: CVX * **Description**: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation * **Code**: 229 * **Code System**: CVX * **Description**: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose |
| For Z22, Z32, and Z42 messages | Per the CDC, the following CVX/VIS mapping addition(s) has/have been made:  Added:   * **CVX Code 215** has been mapped to VIS barcode string 253088698300049311230512 for the **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)** * **CVX Code 216** has been mapped to VIS barcode string 253088698300049311230512 for the **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)**   Modified Description:   * **CVX Code 133 description updated**   + “Pneumococcal conjugate PCV 13”   changed to   * + “**Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)**” | Update(s) has/have been made to the **PHVS\_VISVaccines\_IIS** **Value Set** in the Immunization Test Suite  Added:   * **Code**: 215 * **Code System**: CVX * **Description**: **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)** * **Code**: 216 * **Code System**: CVX * **Description**: **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)**   Modified Description:   * **Code**: 133 * **Code System**: CVX * **Description**: **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20)** |
| For ACK-Z23, RSP-Z31, RSP-Z32, RSP-Z33, and RSP-Z42 messages | Per AIRA, an additional 212 error codes have been created for the ERR-5 (Application Error Code) data element and need to be added to Table HL70533\_IZ in the Immunization Test Suite. | Table HL70533\_IZ has been updated to include AIRA’s additional error codes for the ERR-5 (Application Error Code) data element. The codes provide an expanded set for reporting details of conformance and data quality issues. |
| **ONC 2015 Test Plan**  **Test Case**:  IZ-AD-1\_Admin\_Child  **Test Step**:  IZ-AD-1.1\_Send\_V04\_Z22 | Per the CDC, a new VIS Document Barcode String –**253088698300049311230512** – has been added for the updated version of the **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20) VIS**.  The example Test Message provided for Test Step **IZ-AD-1.1\_Send\_V04\_Z22** includes:  OBX|3|CE|69764-9^Document Type^LN|3|**253088698300049311220204**^Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20) VIS^cdcgs1vis||||||F|||20150624 | In the Test Message for the **IZ-AD-1.1\_Send\_V04\_Z22** Test Step, the **VIS code** in the OBX segment has been changed to:  OBX|3|CE|69764-9^Document Type^LN|3|**253088698300049311230512**^Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20) VIS^cdcgs1vis||||||F|||20150624 |
| **ONC 2015 Test Plan**  **Test Case**:  IZ-AD-8\_Admin\_IIS-Warning  **Test Step**:  IZ-AD-8.1\_Send\_V04\_Z22 | Per the CDC, a new VIS Document Barcode String – **253088698300005911230512** – has been added for the updated version of the **Hepatitis B Vaccine VIS**.  The example Test Message provided for Test Step **IZ-AD-8.1\_Send\_V04\_Z22** includes:  OBX|3|CE|69764-9^Document Type^LN|3|**253088698300005911211015**^Hepatitis B Vaccine VIS^cdcgs1vis||||||F|||20150625 | In the Test Message for the **IZ-AD-8.1\_Send\_V04\_Z22** Test Step, the **VIS code** in the OBX segment has been changed to:  OBX|3|CE|69764-9^Document Type^LN|3|**253088698300005911230512**^Hepatitis B Vaccine VIS^cdcgs1vis||||||F|||20150625 |

| **Message Profile** | **Issue** | | **Resolution** |
| --- | --- | --- | --- |
| For Z22, Z32, Z42 messages | Per the CDC, the following VIS document(s) and VIS Code(s) has/have been added: | | The new VIS document(s) with **Description** and associated VIS **Code** has/have been added to the **PHVS\_VISBarcodes\_IIS Value Set** in the Immunization Test Suite |
|  | **Document Type Description (New)** | **VIS Fully-encoded Test String** |
|  | **Pneumococcal Conjugate Vaccine (PCV13\_PCV15\_PCV20) VIS** | 253088698300049311230512 |
|  | **Hepatitis B Vaccine VIS** | 253088698300005911230512 |

**Specific Validation**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**User Interface**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**Core Functionality**

| **Issue** | **Resolution** |
| --- | --- |
| The updated address location in the WSDL is <https://hl7v2-iz-r1-5-testing.nist.gov/iztool/ws/iisService.wsdl> as of several months ago; but when users try to return the Service, the old address location – <https://hl7v2-iz-r1.5-testing.nist.gov/iztool/ws/iisService> – is being inserted automatically into the SOAP message. | The <https://hl7v2-iz-r1-5-testing.nist.gov/iztool/ws/iisService.wsdl> address is the correct one and has been substituted for the old address in the WSDL. |

**Documentation**

| **Issue** | **Resolution** |
| --- | --- |
| The following files under “User Documentation” on the Documentation Page have errors (e.g., the urls for the Immunization Test Suite are outdated, there are several typos, and “IE 9 and 10” and “IE 9+” are listed as “supported browsers”):   1. Immunization Tool Quick Reference Guide 2. Tutorial: Immunization Tool for HL7v2 Validation 3. Understanding Immunization Meaningful Use Certification Testing 4. NIST Immunization ATL Training 5. Understanding NIST HL7 v2 Validation | Those User Documentation files have been updated (e.g., the urls to the Immunization Test Suite have been changed to <https://hl7v2-iz-r1-5-testing.nist.gov> , typos have been corrected, and “IE 9 and 10” and “IE 9+” have been deleted and replaced with “Edge”). |

**SOAP Functionality**

| **Test Case** | **Issue** | **Resolution** |
| --- | --- | --- |
| None |  |  |

**Improvements/Features**

|  |
| --- |
| None |

**Issues for a Future Release**

**ONC 2015 Test Plan**

| **Test Case/if Applicable** | **Issue** |
| --- | --- |
| All Test Steps with a VXU message | In a VXU Context-based message where there are multiple OBX segments for each Order Group, if an OBX segment has OBX-3.1 populated with the 69764-9 LOINC code and has OBX-5.1 populated with an incorrect VIS ID, the Test Tool issues an Error notification that indicates   * in the **Path** information the VXU Order Group (e.g., “VXU\_V04.ORDER[1]”) within which the OBX with the error is contained and * in the **Line #** information the line number listed in the Message Content window for the ORC segment in that Order Group. * In the **Description** information that an Error has been found due to there being no OBX segment where OBX-3.1 is populated with the 69764-9 LOINC code and OBX-5.1 is populated with [an expected VIS ID] within in this Order Group.   The Path, Line #, and Description information may or may not be meaningful enough for a Tester to determine which OBX segment contains the VIS ID error.  The Tool will be modified to make the Error notification more specific and meaningful. |
| Context-free Data Quality Assurance (DQA) function | The DQA tab in the Context-free / VXU Z22 function has been removed in order to update the capability. The Tool will be modified with an updated version.  (Demonstration of how DQA is intended to function has been deleted from the updated Tool Tutorial.) |